Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alchemab Therapeutics Ltd.
Headquarters: Bloomsbury, United Kingdom
Website: https://alchemab.com/
Year Founded: 2019
Status: Private
BioCentury | Sep 13, 2024
Management Tracks
Sana CFO Hardy to depart
Plus: New CEOs at Alchemab and Genespire, and more from Leyden and Pharmazz
BioCentury | Feb 9, 2024
Management Tracks
Terns names Amy Burroughs CEO
Plus: Disc hires Jean Franchi as CFO, promotes Jonathan Yu to COO, and updates from Domain, Enable Injections and Alchemab
BioCentury | Aug 31, 2023
Management Tracks
Ashrafian to lead Sanofi’s R&D
Serial entrepreneur and VC joins pharma amid other changes to executive committee
BioCentury | May 27, 2022
Management Tracks
Kwon to lead Alchemab as Treco departs
Plus Drew Young to head commercial at Anthos, NRx general counsel leaving
BioCentury | Nov 16, 2021
Management Tracks
End of an era at Biogen as R&D head Sandrock readies to retire
Plus: Levin-Allerhand joins Flagship, and updates from Alchemab, Agios, Actym, Gilgamesh and more
BioCentury | Jun 22, 2021
Management Tracks
Wigerinck to leave Galapagos; plus Kymera, Alladapt, Nurix, Alchemab, Novome and more
Piet Wigerinck will step down this year after serving as CSO for nine years at Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), overseeing the Belgian biotech’s programs from the discovery of
BioCentury | Jun 18, 2021
Finance
Dementia Discovery Fund’s investments: Data Byte
Since its launch by SV Health Investors in 2015 to fund new thinking in Alzheimer’s and other neurological diseases, Dementia Discovery Fund (DDF) has funded one to four companies per year
BioCentury | May 15, 2021
Emerging Company Profile
Median seed, A round sizes have more than doubled since 2017
2021 is turning out to be a bumper year, in particular for start-ups with new modalities
BioCentury | Apr 15, 2021
Emerging Company Profile
How SV-seeded Alchemab is searching for mAbs in super responders
Alchemab attracts RA Capital-led syndicate to £60M series A round
Items per page:
1 - 10 of 13